Bu öğeden alıntı yapmak, öğeye bağlanmak için bu tanımlayıcıyı kullanınız: http://hdl.handle.net/11452/25970
Başlık: Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: An international, multicenter study
Yazarlar: Alptekin, Köksal
Hafez, Jamal
Brook, Shlomo
Tzebelikos, Errikos
Üçok, Alp
Tallawy, Hamdy El
Danacı, Ayşen Esen
Lowe, Wing
Karayal, Onur N.
Uludağ Üniversitesi/Tıp Fakültesi/Psikiyatri Anabilim Dalı.
Akkaya, Cengiz
14061855100
Anahtar kelimeler: Antipsychotics
Haloperidol
Olanzapine
Risperidone
Schizophrenia
Switch
Ziprasidone
Conventional antipsychotics
Rating-scale
Schizophrenia
Improvement
Outpatients
Medications
Strategies
Weight
Pharmacology & pharmacy
Psychiatry
Yayın Tarihi: Eyl-2009
Yayıncı: Lippincott Williams & Wilkins
Atıf: Alptekin, K. vd. (2009). "Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: An international, multicenter study". International Clinical Psychopharmacology, 24(5), 229-238.
Özet: To compare the effectiveness of a switch from haloperidol (N=99), olanzapine (N=82), or risperidone (N=104) to 12 weeks of treatment with 80-160 mg/day ziprasidone in patients with stable schizophrenia or schizoaffective disorder. Stable outpatients with persistent symptoms or troublesome side effects were switched using one of three 1-week taper/switch strategies as determined by the investigator. Efficacy was assessed using the Brief Psychiatric Rating Scale score, Clinical Global Impression, Positive and Negative Symptom Scale, Montgomery-Asberg Depression Rating Scale, and the Global Assessment of Functioning Scale, and tolerability by using standard measures of weight change, extrapyramidal symptoms, and laboratory findings, Suboptimal efficacy was the primary reason for switching. The preferred switch strategy was immediate discontinuation, and the preferred dosing regimen was 120 mg/day. Completer rates were 68, 60, and 86% in the haloperidol, risperidone, and olanzapine pre-switch groups, respectively. At week 12, a switch to ziprasidone resulted in statistically significant improvement from baseline on the Brief Psychiatric Rating Scale score, Clinical Global Impression-improvement, Positive and Negative Symptom Scale, and Global Assessment of Functioning scales, reduction in extrapyramidal symptoms and a neutral impact on metabolic parameters. Switch from olanzapine and risperidone resulted in weight reduction and from haloperidol in some weight increase. In conclusion, oral ziprasidone of 80-160 mg/day with food was a clinically valuable treatment option for stable patients with schizophrenia or schizoaffective disorder experiencing suboptimal efficacy or poor tolerability with haloperidol, olanzapine, or risperidone.
URI: https://doi.org/10.1097/YIC.0b013e32832c2624
https://journals.lww.com/intclinpsychopharm/Fulltext/2009/09000/Efficacy_and_tolerability_of_switching_to.1.aspx
http://hdl.handle.net/11452/25970
ISSN: 0268-1315
Koleksiyonlarda Görünür:Scopus
Web of Science

Bu öğenin dosyaları:
Bu öğeyle ilişkili dosya bulunmamaktadır.


DSpace'deki bütün öğeler, aksi belirtilmedikçe, tüm hakları saklı tutulmak şartıyla telif hakkı ile korunmaktadır.